Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 7:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 342 matching trials from the live ClinicalTrials.gov search.
Conditions
Solitary Bone Plasmacytoma
Interventions
Durvalumab, Radiation therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
dalteparin, lenalidomide, dexamethasone, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Primary Sclerosing Cholangitis
Interventions
Thalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 72 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Breast Cancer
Interventions
nab-paclitaxel, trastuzumab, Doxorubicin, cyclophosphamide, Growth Factor Support, Surgery
Drug · Biological · Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Hays, Kansas • Kansas City, Kansas
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

NCT03863184
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib, Lenalidomide, Rituximab, Obinutuzumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Leukemia, Amyloidosis
Interventions
Lenalidomide, Melphalan, Dexamethasone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Conditions
Multiple Myeloma
Interventions
Thalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Central Nervous System Tumor, Pediatric, Neuroblastoma
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cholangiocarcinoma
Interventions
Nab-Paclitaxel and Gemcitabine
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
24
States / cities
Denver, Colorado • Chicago, Illinois • Oak Lawn, Illinois + 17 more
Conditions
Thyroid Neoplasms
Interventions
Lenalidomide
Drug
Lead sponsor
Kenneth Ain
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
Pomalidomide, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Ajai Chari
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Ph II Study of Azacitidine in Myelofibrosis

NCT00569660
Conditions
Myelofibrosis
Interventions
Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pharmacokinetics
Interventions
CC-220, Rifampin, Itraconazole
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Conditions
Myelodysplastic Syndromes
Interventions
CC-5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
38
States / cities
Scottsdale, Arizona • Tucson, Arizona • Berkeley, California + 28 more
Conditions
Multiple Myeloma
Interventions
Bortezomib, Lenalidomide, Dexamethasone, Vorinostat
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Immunoglobulin G Subclass 4 Related Disease, IgG4-related Disease, Autoimmune Pancreatitis, IgG4-related Sclerosing Cholangitis, Retroperitoneal Fibrosis
Interventions
Rituximab, Lenalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Pancreatic Neoplasms, Pancreatic Cancer, Adenocarcinoma
Interventions
nab-paclitaxel, gemcitabine, capecitabine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
San Francisco, California • Salt Lake City, Utah
Terminated Phase 3 Interventional Results available

BiRd vs. Rd as Initial Therapy in Multiple Myeloma

NCT02516696
Conditions
Multiple Myeloma
Interventions
Clarithromycin, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Conditions
Pancreatic Cancer
Interventions
Pomalidomide, Gemcitabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Aurora, Colorado • Nashville, Tennessee
Completed Phase 1Phase 2 Interventional Results available

Azacitidine and Lenalidomide for Acute Myeloid Leukemia

NCT01016600
Conditions
Leukemia, Myeloid, Acute
Interventions
Lenalidomide, Azacitidine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Multiple Myeloma
Interventions
Bortezomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Bendamustine, Rituximab, Lenalidomide
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
10
States / cities
Green Bay, Wisconsin • Janesville, Wisconsin • La Crosse, Wisconsin + 6 more
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Apremilast and Moderate to Severe Chronic Hand Dermatitis

NCT03741933
Conditions
Chronic Hand Dermatitis
Interventions
Apremilast 30mg
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Multiple Myeloma
Interventions
Azacitidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 69 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Richmond, Virginia